Effectiveness of BNT162b2, mRNA-1273, and ChAdOx1-S vaccines against severe covid-19 outcomes in a nationwide mass vaccination setting: cohort study.

Kim BouillonBérangère BaricaultJérémie BottonMarie-Joëlle JabagiMarion BertrandLaura SemenzatoStéphane Le VuJérôme DrouinRosemary Dray-Spira Alain Weill Mahmoud Zureik

Published in: BMJ medicine (2022)

These findings provide evidence indicating that two doses of ChAdOx1-S is as effective as two doses of mRNA vaccines in France against the alpha and delta variants of SARS-CoV-2. The effectiveness of ChAdOx1-S should be further examined with a longer follow-up and in the light of the circulation of new SARS-CoV-2 variants of concern.

Keyphrases

sars cov
randomized controlled trial
copy number
respiratory syndrome coronavirus
systematic review
binding protein
early onset
coronavirus disease
cross sectional
drug induced